Drugs that contain Enasidenib Mesylate
1. List of Idhifa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9512107 | CELGENE CORP | Therapeutically active compositions and their methods of use |
Jan, 2033
(9 years from now) | |
| US10093654 | CELGENE CORP | Therapeutically active compounds and their methods of use |
Aug, 2034
(11 years from now) | |
| US9738625 | CELGENE CORP | Therapeutically active compounds and their methods of use |
Aug, 2034
(11 years from now) | |
| US9732062 | CELGENE CORP | Therapeutically active compounds and their methods of use |
Sep, 2034
(11 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10610125 | CELGENE CORP | Methods and compositions for cell-proliferation-related disorders |
Jun, 2030
(7 years from now) | |
| US10294215 | CELGENE CORP | Therapeutically active compounds and their methods of use |
Jan, 2033
(9 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Aug 1, 2024 |
| New Chemical Entity Exclusivity (NCE) | Aug 1, 2022 |
NCE-1 date: August, 2021
Market Authorisation Date: 01 August, 2017
Treatment: Treatment of relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation
Dosage: TABLET;ORAL
More Information on Dosage
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic